Clinical trials: Obstructive Pulmonary Disease
Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History
The purpose of the study is to determine if benralizumab reduces COPD exacerbation rate in symptomatic patients with moderate to very severe COPD who are receiving standard of care therapies
- Trial name
- GALATHEA (NCT02138916)
- Testing
- Benralizumab Arm A, Benralizumab Arm B
- Where
- 407 sites in United States, Austria and 15 more
- Volunteers
- 1,656 people
- Sponsor
- AstraZeneca
Asthma
Study to Investigate the Efficacy of Symbicort® SMART.
The primary objective of this study is to compare the efficacy of Symbicort SMART (Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus as needed) with Symbicort Turbuhaler 160/4.5μg, one inhalation twice daily plus…
- Trial name
- SAKURA (NCT00839800)
- Testing
- Symbicort Turbuhaler, Terbutaline Turbuhaler
- Where
- 109 sites in Argentina, Brazil and 10 more
- Volunteers
- 2,091 people
- Sponsor
- AstraZeneca
Non-small Cell Lung Cancer (NSCLC), Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Rehabilitation Before Lung Cancer Resection
This is a study funded by the National Institute of Health. The rationale for the need of this research is the lack of any well proven risk-reducing intervention that may decrease the morbidity of lung cancer resection in…
- Trial name
- NCT02887521
- Testing
- education, rehabilitation, pedometer
- Where
- 7 sites in United States, Canada
- Volunteers
- 9 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Pulmonary Disease, Chronic Obstructive
GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)
This study evaluates the safety of medicine on COPD (Chronic Obstructive Pulmonary Disease). This study will last up to 56 weeks, and subjects will visit the clinic 16 times.
- Trial name
- NCT00269087
- Testing
- fluticasone propionate/salmeterol combination DISKUS
- Where
- 5 sites in Japan
- Volunteers
- 122 people
- Sponsor
- GlaxoSmithKline
Healthy
A Drug Interaction Study to Assess the Pharmacokinetics of Narlaprevir and Antiretroviral Drugs
The study purpose is to evaluate the potential for a pharmacokinetic drug-drug interaction, safety and tolerability when Narlaprevir, Ritonavir (used as a metabolic inhibitor) and Tenofovir disoproxil fumarate (part 1) and…
- Trial name
- NCT03537404
- Testing
- Narlaprevir, Ritonavir, Tenofovir Disoproxil Fumarate
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Asthma
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 and FF in Japanese Subjects With Asthma
The primary purpose of the study is to assess the safety and tolerability of 52-week teatment with fluticasone furoate/GW642444 inhalation powder once-daily and FF inhalation powder once-daily in Japanese adult subjects with…
- Trial name
- NCT01244984
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder, Fluticasone Furoate Inhalation Powder
- Where
- 30 sites in Japan
- Volunteers
- 243 people
- Sponsor
- GlaxoSmithKline
Asthma, Obesity
Pilot Study of Pioglitazone for the Treatment of Moderate to Severe Asthma in Obese Asthmatics (Glitz Asthma)
Asthmatics who are significantly overweight tend to have more severe symptoms, more flare ups, and are more likely to have poorly-controlled asthma when compared to other asthmatics.
- Trial name
- GLITZ (NCT00787644)
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- University of Vermont
Chronic Obstructive Pulmonary Disease
A Phase IIb Study of Glycopyrrolate Inhalation Solution Over 1 Week in Subjects With COPD
This study is a randomized, double-blind, placebo-controlled complete block cross-over study designed to assess the efficacy, safety, and pharmacokinetics of 3 dose levels of glycopyrrolate inhalation solution delivered twice…
- Trial name
- NCT06545500
- Testing
- Glycopyrrolate (85 μg), Glycopyrrolate (42.5 μg), Glycopyrrolate (14 μg)
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
COPD
COPD Access to Pulmonary Rehabilitation Intervention
Persons with COPD have significant functional disability but cannot access rehabilitative treatment at hospital-based conventional pulmonary rehabilitation (PR) programs.
- Trial name
- CAPRI (NCT03794921)
- Testing
- Every Step Counts
- Where
- United States
- Volunteers
- 146 people
- Sponsor
- VA Office of Research and Development
Chronic Obstructive Pulmonary Disease (COPD)
A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD
The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to…
- Trial name
- NCT03573817
- Testing
- Revefenacin, Formoterol
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Mylan Inc.
COPD, Chronic Bronchitis
N-Acetylcysteine for Patients With COPD and Chronic Bronchitis
N-acetylcysteine (NAC) is described as having mucolytic and antioxidant properties. It is widely prescribed for patients with chronic obstructive lung disease (COPD), particularly for those who have accompanying symptoms of…
- Trial name
- NCT01739790
- Testing
- N-Acetylcysteine
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Minnesota
Chronic Obstructive Pulmonary Disease
Neuromuscular Electrical Stimulation in Chronic Obstructive Pulmonary Disease (COPD)
The purpose of this study is to elucidate whether combination of usual pulmonary rehabilitation and neuromuscular electrical stimulation of quadriceps may improve exercise capacity in patients affected by chronic obstructive…
- Trial name
- NCT00677690
- Testing
- neuromuscular electrical stimulation (NMES)
- Where
- Italy
- Volunteers
- 83 people
- Sponsor
- Fondazione Salvatore Maugeri
Pulmonary Disease, Chronic Obstructive
A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
This study evaluated the effect of inhaled aclidinium bromide on exercise endurance and in reducing resting and dynamic lung hyperinflation in patients with moderate to severe COPD.
- Trial name
- NCT00500318
- Testing
- Aclidinium Bromide
- Where
- 52 sites in United States, Canada
- Volunteers
- 181 people
- Sponsor
- AstraZeneca
Rhinitis, Allergic, Perennial, Asthma
Biomarker-based Cockroach Sublingual Immunotherapy Study (BioCSI)
There is currently no effective way to prevent development of allergic rhinitis (nasal allergies) and asthma and no cure. Sublingual immunotherapy (SLIT), a type of therapy in which allergens are placed under the tongue, may be a…
- Trial name
- NCT00829985
- Testing
- Glycerinated German Cockroach Allergenic Extract
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Disease, Chronic Obstructive
Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease
Chronic obstructive pulmonary disease (COPD) is characterized by chronic airflow limitation caused by inflammation-mediated damage to lung tissue.
- Trial name
- NCT01387178
- Testing
- fluticasone propionate/salmeterol 250µg/50µg (FSC), tiotropium bromide (TIO)
- Volunteers
- 22,223 people
- Sponsor
- GlaxoSmithKline
Asthma
Non-Interventional Study to Describe the Clinical Management in Asthmatic Patients (NICMA)
Asthma is a heterogenic chronic disease that affects more than 300 million people worldwide, which it's characterized by acute symptomatic episodes of varying severity, including intermittently inflammation and narrowing of the…
- Trial name
- (NICMA) (NCT06811155)
- Where
- Spain
- Volunteers
- 288 people
- Sponsor
- Hospital Universitario Virgen de la Victoria
Asthma
Safety and Efficacy Study of Budesonide (Pulmicort®) Turbuhaler® in Japanese Children With Bronchial Asthma
This study will include the patients who are Japanese children with bronchial asthma aged 5 years to 15 years old and have completed the Phase III study (Study code: D5254C00769) at about 29 centres.
- Trial name
- NCT00509028
- Testing
- Budesonide, Conventional Asthma Therapy
- Where
- Japan
- Volunteers
- 241 people
- Sponsor
- AstraZeneca
COPD
Effect of Roflumilast on Airway Blood Flow as an Expression of Airway Inflammation in COPD
The objectives of the proposed study are to determine 1) the effect of a single dose of Roflumilast on airway blood flow (Qaw) (study period 1) and 2) the effect of long-term Roflumilast treatment on airway blood flow reactivity…
- Trial name
- NCT02097992
- Testing
- Roflumilast
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Miami
Asthma
A Randomized Trial Examining the Effectiveness of Mobile-Based Asthma Action Plans vs. Paper Asthma Action Plans
The purpose of this study is to see if using a mobile phone application asthma action plan will help improve asthma management.
- Trial name
- PEAK2 (NCT02091869)
- Testing
- Paper Asthma Action Plan, Mobile Phone
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Arkansas Children's Hospital Research Institute
Asthma
Montelukast in Pediatric Patients Aged 6 to 24 Months With Asthma--Safety Study (0476-176)
A study of Montelukast compared to placebo in asthmatic children aged 6-24 months.
- Trial name
- NCT00943683
- Testing
- montelukast sodium
- Volunteers
- 256 people
- Sponsor
- Organon and Co
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.